BREAST CANCER BASE

For the treatment of breast cancer, in addition to traditional surgery and radiotherapy and chemotherapy, in recent years the medical profession also rise against a recurrence of breast cancer and advanced breast cancer treatment — endocrine therapy.

However, the Zhongshan University Cancer Hospital director Dr. thoracic surgery, breast chief expert Professor Tim Young who, in a recent press interview, endocrine therapy only to those hormones (estrogen and progestin) receptor-positive patients in the role, and such people in breast cancer patients about 70%. Therefore, not every one of breast cancer patients are required to undergo hormonal therapy.

Endocrine drugs with easy-to-use, fast in extensive clinical applications, and to replace the endocrine glands (ovary, adrenal and pituitary) castration trend. Currently more clinical breast cancer patients according to the menses (that is, whether menopause) to choose a different type of endocrine treatment. The goal of treatment, amenorrhea against ovarian ago, after amenorrhea to cut off the sources of estrogen or estrogen inhibition of the main activities. As selection criteria, endocrine drugs can improve the efficacy of treatment.
Endocrine drugs treatment by the end of the cancer or estrogen antagonist, inhibited the effect of estrogen, tumor regression. Furthermore, it will eliminate micro metastasis, and improve the living quality and disease-free survival.

The breast itself is an endocrine organ, the incidence of breast cancer and the body endocrine dysfunction. The endocrine therapy in breast cancer is through endocrine organ removal and endocrine drugs used to treat breast cancer, a method.
Endocrine therapy has the following four characteristics :
(1) Determination of tumor cells in the ER and PR to predict the level of endocrine treatment efficacy.
(2) produce a slower, the general observation should be at least a month. If conditions ease their remission period can be maintained for more than one year.
(3) endocrine therapy of acute drug toxicity and lower long-term toxicity.
(4) As long as endocrine therapy and many other therapy One of the therapies effective for other possibilities of effective therapies are great.
Endocrine therapy in breast cancer treatment as one of the means, mainly apply to pre-menopausal and hormone receptor positive breast cancer patients, and not suitable for surgery or radiotherapy in the treatment of advanced breast cancer patients, and the rapid development of inflammatory breast cancer and breast cancer recurrence or metastasis of milk there adenocarcinoma, particularly estrogen receptor-positive patients, it should consider endocrine therapy. 

Aromatase inhibitors (ve class — AI) is the study of endocrine therapy for breast cancer the most active part. With the third generation of AI research and development and in-depth applications, tamoxifen (TAM) in the treatment of breast cancer endocrine status of the standards being challenged, Femara (letrozole) in the most clinical research system, the conclusion most certainly against recurrence of the metastases second-line treatment of the rescue good results in ammonia Mian-guided energy (AR/BC2 pilot) and megestrol acetate (AR/BC3 test); femara frontline rescue therapy (025 tests) and preoperative new secondary treatment (024 tests), they are significantly better than TAM; Although TAM compared with the postoperative adjuvant treatment, a million people the largest group of international clinical trials (MA17 NCIC CTG and BIG1-98 pilot) also ongoing, but is expected to get better results.